Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 28;16(9):1719.
doi: 10.3390/cancers16091719.

The Role of Surgery in Pleural Mesothelioma

Moshe Lapidot  1   2 , Martin Sattler  3
Affiliations
Review

The Role of Surgery in Pleural Mesothelioma

Moshe Lapidot et al. Cancers (Basel). .

Abstract

Surgery plays a central role in the diagnosis, staging, and management of pleural mesothelioma. Achieving an accurate diagnosis through surgical intervention and identifying the specific histologic subtype is crucial for determining the appropriate course of treatment. The histologic subtype guides decisions regarding the use of chemotherapy, immunotherapy, or multimodality treatment. The goal of surgery as part of multimodality treatment is to accomplish macroscopic complete resection with the eradication of grossly visible and palpable disease. Over the past two decades, many medical centers worldwide have shifted from performing extra-pleural pneumonectomy (EPP) to pleurectomy decortication (PD). This transition is motivated by the lower rates of short-term mortality and morbidity associated with PD and similar or even better long-term survival outcomes, compared to EPP. This review aims to outline the role of surgery in diagnosing, staging, and treating patients with pleural mesothelioma.

Keywords: extra-pleural pneumonectomy; macroscopic complete resection; pleural mesothelioma; pleurectomy decortication; surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Baas P., Scherpereel A., Nowak A.K., Fujimoto N., Peters S., Tsao A.S., Mansfield A.S., Popat S., Jahan T., Antonia S., et al. First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet. 2021;397:375–386. doi: 10.1016/S0140-6736(20)32714-8. - DOI - PubMed
    1. Forde P.M., Anagnostou V., Sun Z., Dahlberg S.E., Kindler H.L., Niknafs N., Purcell T., Santana-Davila R., Dudek A.Z., Borghaei H., et al. Durvalumab with Platinum-Pemetrexed for Unresectable Pleural Mesothelioma: Survival, Genomic and Immunologic Analyses from the Phase 2 PrE0505 Trial. Nat. Med. 2021;27:1910–1920. doi: 10.1038/S41591-021-01541-0. - DOI - PMC - PubMed
    1. Van Gerwen M., Alpert N., Wolf A., Ohri N., Lewis E., Rosenzweig K.E., Flores R., Taioli E. Prognostic Factors of Survival in Patients with Malignant Pleural Mesothelioma: An Analysis of the National Cancer Database. Carcinogenesis. 2019;40:529–536. doi: 10.1093/carcin/bgz004. - DOI - PMC - PubMed
    1. Kindler H.L., Ismaila N., Armato S.G., Bueno R., Hesdorffer M., Jahan T., Jones C.M., Miettinen M., Pass H., Rimner A., et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2018;36:1343–1373. doi: 10.1200/JCO.2017.76.6394. - DOI - PMC - PubMed
    1. Pleural M. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) NCCN Guidelines for Patients®. 2023. [(accessed on 20 December 2023)]. Available online: www.nccn.org/patients.

LinkOut - more resources